CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties.
Open Access
- 1 January 1998
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 101 (1), 120-127
- https://doi.org/10.1172/jci1140
Abstract
The clinical potential of the p53 tumor suppressor gene is being evaluated currently for gene therapy of cancer. We have built a variant of wild-type p53, chimeric tumor suppressor 1 (CTS1), in which we have replaced the domains that mediate its inactivation. CTS1 presents some very interesting properties: (a) enhanced transcriptional activity; (b) resistance to the inactivation by oncogenic forms of p53; (c) resistance to the inactivation by MDM2; (d) lower sensitivity to E6-induced degradation; (e) ability to suppress cell growth; and (f ) faster induction of apoptosis. Thus, CTS1 is an improved tumor suppressor and an alternative for the treatment of wild-type p53-resistant human tumors by gene therapy.This publication has 44 references indexed in Scilit:
- p53 Mutation and MDM2 amplification in human soft tissue sarcomas.1993
- p53 Mutations in Human CancersScience, 1991
- Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformationCell, 1991
- Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.Molecular and Cellular Biology, 1991
- The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53Cell, 1990
- Presence of a Potent Transcription Activating Sequence in the p53 ProteinScience, 1990
- Structural aspects of the p53 protein in relation to gene evolution.1990
- Rearrangement of the p53 gene in human osteogenic sarcomas.Proceedings of the National Academy of Sciences, 1987
- ras GENESAnnual Review of Biochemistry, 1987
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970